acetylcysteine oral / Generic mfg. - LARVOL DELTA

Protective effects of Aloe vera extract against doxorubicin-induced degeneration in ovarian follicles and stromal cells in mice. (PubMed, Braz J Med Biol Res) - "The positive control group mice received pretreatment of N-acetylcysteine orally (po), followed by a single intraperitoneal (ip) dose of DOX after 1 h (NAC+DOX). Furthermore, 0.1 and 1.0 mg/kg Aloe vera reduced TNF-α protein expression and increased NRF2, SOD, and CAT mRNA levels. In conclusion, 0.1 and 1.0 mg/kg Aloe vera had protective effects against DOX-induced degeneration in ovarian follicles and stromal cells in mice."

Journal • Preclinical • Oncology • CAT • TNFA

PREEMPTIVE TMP-SMX/N-ACETYLCYSTEINE PROPHYLAXIS MITIGATES THE INCIDENCE OF INTERSTITIAL PNEUMONIA IN DLBCL IMMUNOCHEMOTHERAPY: A DUAL-CENTER COHORT STUDY ON RISK STRATIFICATION AND CLINICAL OUTCOMES (EHA 2025) - "Background: Interstitial pneumonia (IP) is a common and potentially life-threatening complication in newly diagnosed CD20-positive diffuse large B-cell lymphoma () patients receiving rituximab-based immunochemotherapy. The effectiveness of prophylactic use of trimethoprim-sulfamethoxazole (TMP-SMX), either alone or in combination with N-acetylcysteine effervescent tablets, in reducing the risk of IP remains unclear and warrants further investigation... In this cohort of newly diagnosed patients, interstitial pneumonia (IP) occurred in 22.8% of cases, with pre-existing pulmonary disease (adjusted HR=3.12, 95% CI=1.89-5.14) and absence of TMP-SMX prophylaxis (HR=2.98, 95% CI=1.72-5.16) identified as key modifiable risk factors. Crucially, dual prophylaxis with TMP-SMX and N-acetylcysteine reduced IP incidence by 86% compared to untreated controls (ARR=19.7%, P<0.001). Lenalidomide-based regimens independently increased IP risk (HR=2.31, 95% CI=1.45-3.67), underscoring..."

Clinical • Clinical data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Interstitial Lung Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • CD20

Medication Development for Cannabis Use Disorder and Cannabis Withdrawal (CPDD 2025) - "First, a 12-week randomized controlled trial found significant reductions in cannabis use outcomes with varenicline treatment combined with medical management compared to placebo treatment...Second, treatment-seeking youth with CUD were randomized to receive a double-blind 12-week course of oral N-acetylcysteine (NAC) 1200 mg or placebo twice daily; all received weekly medical management and brief behavioral counseling. No difference in cannabis use reduction or cessation outcomes was noted between participants in the NAC and placebo groups, suggesting that NAC is not efficacious for youth CUD when not paired with contingency management. Finally, a phase 2 randomized multi-center double-blind, multiple dose, placebo-controlled clinical trial demonstrated that a unique 34-day taper/titration with nabilone and gabapentin (PP-01) significantly mitigated withdrawal symptoms and decreased cannabis use compared to placebo in adults with moderate to severe CUD seeking to..."

Substance Abuse

NAC Attack: Oral N-acetylcysteine for Retinitis Pigmentosa (clinicaltrials.gov) - P3 | N=483 | Recruiting | Sponsor: Johns Hopkins University | Trial completion date: Dec 2028 ➔ May 2029 | Trial primary completion date: Dec 2028 ➔ May 2029

Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Efficacy, Safety, and Cost-Effectiveness of N-Acetylcysteine in Preventing Amphotericin B Nephrotoxicity in Egyptian Patients with Hematological Malignancies: A Randomized Controlled Trial. (PubMed, Hosp Pharm) - P=N/A | "This study evaluated the efficacy, safety, and cost-effectiveness of oral N-acetylcysteine (NAC) in preventing AmB-d nephrotoxicity and promoting renal recovery in Egyptian hematological malignancy patients. The favorable NNT for renal recovery suggests clinical relevance, warranting further investigation in larger studies. Trial registration: ClinicalTrials.gov identifier, NCT06122311."

HEOR • Journal • Acute Kidney Injury • Hematological Disorders • Hematological Malignancies • Infectious Disease • Nephrology • Oncology • Renal Disease

N-acetylcysteine enhances the antipsychotic effect of aripiprazole in the neurodevelopmental rat model of schizophrenia. (PubMed, Pharmacol Biochem Behav) - "The schizophrenia-like behavior was induced in Sprague-Dawley male pups in the neonatal days p5-p16 by repeated administration of the glutathione synthesis inhibitor L-butionine-(S,R)-sulfoximine (BSO) given together with the dopamine reuptake inhibitor 1-[2-[Bis-4(fluorophenyl)methoxy]ethyl]-4-3-(3-phenylpropyl) (GBR 12909)...Moreover, repeated co-treatment with low doses of ARI with NAC also reversed schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia. The above results indicated that NAC enhanced the action of ARI in the used neurodevelopmental rat model of schizophrenia, and the mechanism of action of the used drugs in this model is discussed."

Journal • Preclinical • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Incidence and predictors of linezolid-associated thrombocytopenia in critically Ill patients: nomogram development based on comprehensive screening of over 70 factors. (PubMed, Expert Rev Anti Infect Ther) - "Protective factors were surgery (OR 0.34, p < 0.01), IV N-acetylcysteine (OR 0.12, p < 0.01), oral N-acetylcysteine (OR 0.17, p < 0.01), higher baseline platelets (OR 0.79, p = 0.05), and acetaminophen (OR 0.42, p < 0.01)...Prolonged therapy, solid organ tumors, dialysis, high lactate, and vasopressor use increase risk; high platelet counts, N-acetylcysteine, and IV acetaminophen decrease risk. External validation and prospective trials are warranted."

Journal • Critical care • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia

Efficacy of Adding Oral N acetyl Cysteine Supplement to the Cystic Fibrosis Treatment Regimen: A Randomized Quasi-Experimental Trial. (PubMed, J Res Pharm Pract) - "Overall, comparisons of forced vital capacity (FVC) between the groups showed no variation. The indicators of FEV1, FVC, FEV1/FVC, forced expiratory flow between 25% and 75% of vital capacity, and the quality of life of the case group were not significantly different from those of the placebo group, and no significant differences were observed between this medicine and placebo."

Journal • Cardiovascular • Cystic Fibrosis • Genetic Disorders • Immunology • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases

Effect of high-dose N-acetyl cysteine on the clinical outcome of patients with diabetic peripheral neuropathy: a randomized controlled study. (PubMed, Diabetol Metab Syndr) - P4 | "High dose NAC administered for 12 weeks modulated inflammation by reducing TNF-alpha and increasing GPx and NRF2 versus controls. NAC improved clinical outcomes of DPN reflected by a decline in neuropathy and pain scores and an improvement in QOL."

Clinical • Clinical data • Journal • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Mood Disorders • Oncology • Pain • Peripheral Neuropathic Pain • Psychiatry • TNFA

N-acetylcysteine for youth cannabis use disorder: randomized controlled trial main findings. (PubMed, Neuropsychopharmacology) - P2/3 | "Treatment-seeking youth with cannabis use disorder (N = 192, ages 14-21) were randomized to receive a double-blind 12-week course of oral N-acetylcysteine 1200 mg or placebo twice daily; all received weekly medical management and brief behavioral counseling. More N-acetylcysteine than placebo treated participants reported gastrointestinal adverse events (63/98 versus 37/94, χ21 = 11.9 p < 0.001); adverse events were otherwise similar between groups. Findings indicate that N-acetylcysteine is not efficacious for youth cannabis use disorder when not paired with contingency management, highlighting the potentially crucial role of a robust behavioral treatment platform in facilitating prior positive efficacy findings with N-acetylcysteine.Trial Registration: Clinicaltrials.gov identifier NCT03055377."

Journal • Gastrointestinal Disorder • Substance Abuse

The Safety and Effectiveness of Taneasy and Actein in COPD Patients (clinicaltrials.gov) - P4 | N=42 | Completed | Sponsor: Bun Yao Biotechnology Co., Ltd | Enrolling by invitation ➔ Completed | N=60 ➔ 42

Enrollment change • Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Retrospective Review of Oral N-Acetylcysteine for Habit-Driven Cutaneous Disorders. (PubMed, Pediatr Dermatol) - "We retrospectively evaluated the therapeutic use and safety of oral NAC in 93 children from the Children's Hospital of Philadelphia. This study supports the use of oral NAC for habit-driven skin, hair, and nail abnormalities in pediatric patients."

Journal • Retrospective data • CNS Disorders • Mental Retardation • Pediatrics • Psychiatry

Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity (clinicaltrials.gov) - P2/3 | N=180 | Recruiting | Sponsor: Ain Shams University | Not yet recruiting ➔ Recruiting

Enrollment open

The Safety and Effectiveness of Taneasy and Actein in COPD Patients (clinicaltrials.gov) - P4 | N=60 | Enrolling by invitation | Sponsor: Bun Yao Biotechnology Co., Ltd

New P4 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Oral N-acetylcysteine ameliorates liver fibrosis and enhances regenerative responses in Mdr2 knockout mice. (PubMed, Sci Rep) - "Spatial protein analysis revealed cell-type specific differential response to NAC, collectively indicating a transition from pro-apoptotic into proliferative state. NAC treatment should be further investigated as a potential therapeutic option for human cholangiopathies."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • ABCB4

Watch Out for Off-Label Weight Loss Medication Use: Zonisamide-Induced Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Drug Induced Liver Injury (ACG 2024) - "She received intravenous (IV) n-acetylcysteine, oral ursodiol, and daily IV methylprednisolone...Dupilumab was initiated to help wean prednisone and cyclosporine...G. Liver chemistries over clinical course."

Cardiovascular • Cholestasis • Dermatitis • Dermatology • Eosinophilia • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Hypertension • Immunology • Infectious Disease • Liver Failure • Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Septic Shock

Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity (clinicaltrials.gov) - P2/3 | N=180 | Not yet recruiting | Sponsor: Ain Shams University

New P2/3 trial

Oral N-Acetylcysteine Use for Acetaminophen Toxicity in an Infant (AAP-NCE 2024) - "Oral NAC is a safe and effective means to treat acetaminophen toxicity in pediatric patients in many cases. Oral therapy should be considered in cases where a patient may be at higher risk of complications of IV therapy such as hyponatremia or volume overload. This case demonstrates a positive outcome with oral NAC therapy and no adverse effects from treatment."

Cardiovascular • Heart Failure • Pediatrics

Lack of efficacy of oral N-acetylcysteine ​​in the treatment of facial melasma in women: a randomized, double-blind, placebo-controlled clinical trial. (PubMed, An Bras Dermatol) - No abstract available

Clinical • Journal • Dermatology • Dermatopathology

A new meaning to "picking your nose": The first use of N-acetylcysteine to successfully treat trigeminal trophic syndrome. (PubMed, Clin Exp Dermatol) - "We present a case of trigeminal trophic syndrome in an elderly lady who successfully responded to oral N-acetylcysteine. An increased awareness of this rare syndrome and potential treatment options will encourage a prompt diagnosis and possibly prevent permanent disfiguration."

Journal • Cardiovascular

Impact of Thermo-Responsive N-Acetylcysteine Hydrogel on Dermal Wound Healing and Oral Ulcer Regeneration. (PubMed, Int J Mol Sci) - "The study concludes that modifying viscosity enhances NAC retention, facilitating tissue regeneration. These findings support previous research on the beneficial effects of antioxidant application on damaged tissues, suggesting the potential of NAC hydrogels in improving wound care and oral ulcer treatment."

Journal • Inflammation

Comparison of therapeutic effects of N-Acetylcysteine with pregabalin in improving the clinical symptoms of painful diabetic neuropathy: a randomized, double-blind clinical trial. (PubMed, Clin Diabetes Endocrinol) - "NAC is efficacious in alleviate symptoms of PDN which is probably related to its antioxidant effects."

Clinical • Journal • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Pain • Type 2 Diabetes Mellitus • CAT

N-Acetylcysteine for Adolescent Alcohol Use Disorder (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: Medical University of South Carolina | Active, not recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ Feb 2024

Trial completion • Trial completion date • Addiction (Opioid and Alcohol)

N-Acetylcysteine for Youth Cannabis Use Disorder (clinicaltrials.gov) - P2/3 | N=192 | Completed | Sponsor: Medical University of South Carolina | Active, not recruiting ➔ Completed

Trial completion • Substance Abuse

Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (clinicaltrials.gov) - P1/2 | N=46 | Recruiting | Sponsor: Tanta University

New P1/2 trial • Pancreatitis • IL10 • TNFA